Lates News

Shutai Shen continued to rise sharply in early trading, with a gain of over 14%; Shutai Shen announced that the company had noticed the high level of attention in the market to the information about the "Priority Review Variety Publicity" column on the website of the Drug Evaluation Center of the National Medical Products Administration about the application of the company's controlling subsidiary Jiangsu Beijetai Biological Technology Co., Ltd. for "Injection STSP-0601"; the drug is currently in the public notice period, with the deadline for public notice being June 3, 2025. There is still a lot of uncertainty about whether the drug will enter the priority review process after the public notice period expires.